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Available online 25 May 2016AbstractOccult breast cancer presenting as an axillary mass is a rare clinical finding. Less than 5% of breast carcinoma presents as an axillary mass
without an obvious primary tumor. Axillary lymph node showing metastatic adenocarcinoma poses diagnostic and therapeutic problems, when it
is the only clinical presentation. In a significant proportion of breast cancer cases, mammographic detection of micro-calcifications is indicative
of the presence of a breast lesion. We present a rare case of a bilateral occult breast carcinoma in a 40 year female with bilateral axillary mass
without any palpable breast mass.
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Occult primary breast cancer, first described in 1907 by
Halsted can be defined as histologically proven breast cancer
discovered outside the breast in the absence of a primary
breast tumor. The incidence of occult primary breast cancer is
0.3e1.0% of all diagnosed breast cancers [1]. Occult breast
cancer presenting as an axillary mass is a rare clinical finding.
Axillary lymph node showing metastatic adenocarcinoma
poses diagnostic and therapeutic problems, when it is the only
clinical presentation.
In breast carcinomas, 30e50% show mammary calcifica-
tions and mammographic detection of micro-calcifications
constitutes one of the most important diagnostic tool [2].
The value of mammography in detecting an occult breast
carcinoma is low, with a sensitivity of 29% and specificity of* Corresponding author. Department of Pathology, Jawaharlal Nehru Medi-
cal College, A.M.U., Aligarh, U.P, India.
E-mail address: drkafilakhtar@gmail.com (K. Akhtar).
Peer review under responsibility of Shanghai Hengrun Biomedical
Technology Research Institute.
http://dx.doi.org/10.1016/j.jocit.2016.05.001
2352-1775/Copyright © 2016, Shanghai Hengrun Biomedical Technology Researc
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/473% but magnetic resonance imaging (MRI) and positron
emission tomography (PET) are potentially more sensitive [3].
Here, we report a rare case of bilateral occult primary
breast cancer with a unique initial presentation with review of
literature on diagnosis, treatment and prognosis of this rare
presentation.2. Case summary
A 40-year-old female presented in the surgical clinic with
bilateral axillary mass for the last 4 months without any other
significant complaints. She did not have any contributory past
or family history and she never used any form of hormonal
contraceptives in the past. Each of the axillary mass was
3  4 cm in size and firm to hard in consistency. Both breast
were normal on examination. General physical and systemic
examinations were within normal parameters. Fine needle
aspiration cytology of the bilateral axillary mass showed
atypical cells, highly suggestive of metastatic adenocarcinoma
(Fig. 1). Excision biopsy of the mass revealed invasive ductal
carcinoma. Subsequently mammography and immunomarkers
ER, PR, and HER2/neu were advised. Bilateral mammogramh Institute. Publishing services by Elsevier B.V. This is an open access article
.0/).
Fig. 1. Fine needle aspiration cytology of the bilateral axillary mass showed
atypical cells, with high N/C ratio, hyperchromatic nucleus, in acini formation,
highly suggestive of metastatic adenocarcinoma. Hematoxylin and Eosin x
40X.
Fig. 3. Immunohistochemistry showed nuclear positivity of estrogen receptors.
IHC ER x 40X.
Fig. 4. Infiltrating Ductal Carcinoma showed cords and sheets of pleomorphic
ductal cells with coarse nuclear chromatin and mild eosinophilic cytoplasm
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picious for malignancy (Fig. 2). Immunohistochemistry was
positive for HER2/neu, estrogen and progesterone receptors
(Fig. 3). The patient underwent bilateral modified radical
mastectomy with bilateral axillary lymph node (ALN)
dissection. The final pathological report revealed a
0.4  0.4 cm primary tumor in the upper inner quadrant of the
right breast and 0.7  0.6 cm lesion in the lower outer
quadrant of the left breast with cords and sheets of pleomor-
phic ductal cells infiltrating the stroma (Fig. 4). 5/6 of the
lymph nodes sampled from both the axilla showed presence of
ductal tumor cells. A final diagnosis of bilateral invasive
ductal carcinoma with metastasis to bilateral axillary lymph
nodes with TNM Stage T1N2M0 was made. Subsequently
patient was subjected to 6 cycles of paclitaxel and adriamycin
based chemotherapy at an interval of 3 weeks, radiationFig. 2. Mammogram showed diffuse micro-calcifications in the breast tissue,
suspicious for malignancy.
infiltrating the stroma with lymphocytic infiltrate. Hematoxylin and Eosin x
40X.therapy in the form of 50 Gy of Co-60  25 fractions,
tamoxifen hormonal therapy, 20 mg daily  5years and tras-
tuzumab 400 mg/m2  4 weekly  12 cycles. Our patient is
doing well on 1 year of follow up with no signs of recurrence.
3. Discussion
Rarely, a breast cancer patient has histologically proven
breast cancer found outside the breast without a detectable
primary breast tumor. Almost always the site of detected
disease is an axillary lymph node. The incidence of axillary
breast cancer with occult primary is relative low, with a peak
incidence at the age of 55 years [1,2]. Malignant tumors from
other sites like lung, thyroid, gastrointestinal tract, ovary etc.
also can spread to axilla, however, the most common source of
primary tumor is the ipsilateral breast, unless proven otherwise
[2,3]. Diagnosis and treatment remain challenging in these
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nancy and mastectomy with axillary clearance are usually
recommended [2,3]. Historically, 20e30% with occult pri-
mary breast cancer have reported a family history of breast
cancer, although this was not the case in our patient [4].
Diagnostic workup for an axillary metastasis must first rule
out other primary sites of disease. Emi et al. [5] have reported
that in a female patient in such situation, investigations other
than related to breast cancer are unnecessary. A thorough
history taking, physical examination, fine needle aspiration
cytology of the palpable axillary lymph node, chest X-ray,
ultrasound of the abdomen, screening blood work, mammo-
gram and/or MRI of the breast are sufficient as the recom-
mended diagnostic tools for locating potential sites of primary
carcinoma [6]. Imaging of the breast for occult primary breast
cancer includes breast ultrasound and MRI. MRI's high
sensitivity for breast tumors may optimize diagnostic accuracy
and, in turn, disease management [7]. Estrogen and proges-
terone receptor status with estimation of HER2/neu are very
useful to classify the tumor with a molecular criterium that is
useful for diagnosis and to plan the treatment [8].
Traditionally occult primary breast cancers were treated
with mastectomy and axillary lymph node dissection; how-
ever, with the advent of breast MRI and improvement in ra-
diation techniques, the management of this rare entity is
changing [9]. If a primary site is identified, the patient should
undergo appropriate surgical management with a lumpectomy
or mastectomy with lymph node evaluation. Occult primary
breast cancer has traditionally been treated with ipsilateral
mastectomy and axillary lymph node (ALN) dissection [9,10].
In terms of definitive therapy for occult primary breast
cancer, breast conserving therapy (BCT) or mastectomy with
ALND provides equivalent survival and recurrence outcomes,
and the practice of BCT is steadily increasing. Khandelwal
and Garguilo [11] reported 50% recurrence rate when the
axilla is treated only with radiotherapy in comparison to
axillary dissection (<10%). ALN biopsy (without formal
axillary dissection) followed by RT to axilla also showed
higher recurrence (20e50%) as well. They concluded that
ALN dissection as an essential component for better loco-
regional control of disease for such patients. In case of fixed
unresectable ALN, neoadjuvant chemotherapy and hormone
therapy depending on hormone receptor status followed by
ALN dissection could be a valid option [11e13]. We
emphasize that aggressive approach and detail clinical history
with thorough examination should be undertaken, in a woman
with metastatic adenocarcinoma in the ALN.Conflict of interests
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